banner

Transforming Liver
Health

EBDLR v2.0 – it is lightweight, portable, and budget-friendly solution
to fight acute liver failure.

Latest Updates
  • Indian Patent Granted
  • US Patent Granted
  • CDSCO Approval received for Pilot Study
problem

Problem

Acute Liver Failure (ALF) is a life-threatening illness with a high mortality rate of up to 50-75%. It can progress rapidly, with liver failure developing within days to weeks after the onset of symptoms, without any prior existing liver disease.

Acute-on-Chronic Liver Failure (ACLF) is a serious and life-threatening condition that occurs in people who already have chronic liver disease. It develops suddenly, often triggered by infections, alcohol use, or other stressors on the liver. ACLF can worsen quickly over days to weeks and is associated with a high risk of death, with a one-year mortality rate of around 40–50%.

Unfortunately, liver transplant surgery is currently the only available treatment, but it's expensive and constrained by limited organ availability.

KNOW MORE
Solution

Solution

The EBDLR v2.0 is a state-of-the-art device built specifically to supplement the liver and enable it to regenerate itself with the support of the device.

KNOW MORE

Promising Results

The Pre-clinical studies have demonstrated promising results in rescuing subjects with ALF.

KNOW MORE

Patents

Ykrita Lifesciences has filed three patents for the EBDLR System in India, the PCT, and the USPTO, emphasizing the device's innovative nature and potential life-saving impact.

KNOW MORE

Journey to Self Reliance

From research facilities at IISc & C-CAMP
to a self-reliant facility
Journey Timeline